Literature DB >> 29472347

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Ankush Bhatia1, Gary Ulaner2, Raajit Rampal3, David M Hyman3, Omar Abdel-Wahab3, Benjamin H Durham3, Ahmet Dogan4, Neval Ozkaya4, Mario E Lacouture3, Julio Hajdenberg5, Chezi Ganzel6, Eli L Diamond7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472347      PMCID： PMC5865413          DOI： 10.3324/haematol.2017.185298

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

2.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

5.  Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Authors:  David M Hyman; Eli L Diamond; Cecile Rose T Vibat; Latifa Hassaine; Jason C Poole; Minal Patel; Veronica R Holley; Goran Cabrilo; Timothy T Lu; Maria E Arcila; Young Rock Chung; Raajit Rampal; Mario E Lacouture; Neal Rosen; Funda Meric-Bernstam; José Baselga; Razelle Kurzrock; Mark G Erlander; Filip Janku; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2014-10-16       Impact factor: 39.397

Review 6.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

7.  Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.

Authors:  Baptiste Hervier; Julien Haroche; Laurent Arnaud; Frédéric Charlotte; Jean Donadieu; Antoine Néel; François Lifermann; Carles Villabona; Bruno Graffin; Olivier Hermine; Aude Rigolet; Camille Roubille; Eric Hachulla; Thierry Carmoi; Maud Bézier; Véronique Meignin; Marie Conrad; Laurence Marie; Elise Kostrzewa; Jean-Marie Michot; Stéphane Barete; Valerie Taly; Karine Cury; Jean-François Emile; Zahir Amoura
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

8.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

9.  Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA.

Authors:  David Hunt; Paul Milne; Peter Fernandes; Venetia Bigley; Matthew Collin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-11-03

Review 10.  Dabrafenib and its potential for the treatment of metastatic melanoma.

Authors:  Alexander M Menzies; Georgina V Long; Rajmohan Murali
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162
View more
  16 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

2.  Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease.

Authors:  Gordon J Ruan; Antonious Hazim; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Leuk Lymphoma       Date:  2020-07-01

3.  Highly sensitive methods are required to detect mutations in histiocytoses.

Authors:  Sarah Melloul; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; Sylvie Fraitag; Nathalie Terrones; Quentin Riller; Thibaud Chazal; Sébastien Héritier; Anne Moreau; Marianne Kambouchner; Marie Christine Copin; Jean Donadieu; Valérie Taly; Zahir Amoura; Julien Haroche; Jean François Emile
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 4.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

5.  Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.

Authors:  Sonia Mahajan; Reiko Nakajima; Mariko Yabe; Ahmet Dogan; Gary A Ulaner; Joachim Yahalom; Ariela Noy; Eli L Diamond; Heiko Schöder
Journal:  Clin Nucl Med       Date:  2020-06       Impact factor: 7.794

6.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

Review 7.  MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.

Authors:  Rikhia Chakraborty; Omar Abdel-Wahab; Benjamin H Durham
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

8.  ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.

Authors:  Paul G Kemps; Jennifer Picarsic; Benjamin H Durham; Zofia Hélias-Rodzewicz; Laura Hiemcke-Jiwa; Cor van den Bos; Marianne D van de Wetering; Carel J M van Noesel; Jan A M van Laar; Robert M Verdijk; Uta E Flucke; Pancras C W Hogendoorn; F J Sherida H Woei-A-Jin; Raf Sciot; Andreas Beilken; Friedrich Feuerhake; Martin Ebinger; Robert Möhle; Falko Fend; Antje Bornemann; Verena Wiegering; Karen Ernestus; Tina Méry; Olga Gryniewicz-Kwiatkowska; Bozenna Dembowska-Baginska; Dmitry A Evseev; Vsevolod Potapenko; Vadim V Baykov; Stefania Gaspari; Sabrina Rossi; Marco Gessi; Gianpiero Tamburrini; Sébastien Héritier; Jean Donadieu; Jacinthe Bonneau-Lagacherie; Claire Lamaison; Laure Farnault; Sylvie Fraitag; Marie-Laure Jullié; Julien Haroche; Matthew Collin; Jackie Allotey; Majid Madni; Kerry Turner; Susan Picton; Pasquale M Barbaro; Alysa Poulin; Ingrid S Tam; Dina El Demellawy; Brianna Empringham; James A Whitlock; Aditya Raghunathan; Amy A Swanson; Mariko Suchi; Jon M Brandt; Nabeel R Yaseen; Joanna L Weinstein; Irem Eldem; Bryan A Sisk; Vaishnavi Sridhar; Mandy Atkinson; Lucas R Massoth; Jason L Hornick; Sanda Alexandrescu; Kee Kiat Yeo; Kseniya Petrova-Drus; Stephen Z Peeke; Laura S Muñoz-Arcos; Daniel G Leino; David D Grier; Robert Lorsbach; Somak Roy; Ashish R Kumar; Shipra Garg; Nishant Tiwari; Kristian T Schafernak; Michael M Henry; Astrid G S van Halteren; Oussama Abla; Eli L Diamond; Jean-François Emile
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

Review 9.  Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.

Authors:  Masayuki Kobayashi; Arinobu Tojo
Journal:  Cancer Sci       Date:  2018-10-30       Impact factor: 6.716

10.  High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.

Authors:  Lynn H Lee; Christa Krupski; Jason Clark; Mark Wunderlich; Robert B Lorsbach; Michael S Grimley; Matthew Burwinkel; Adam Nelson; Ashish R Kumar
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.